Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $24.4 million.

  • Cytosorbents' Non-Current Assets fell 2169.3% to $24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.6 million, marking a year-over-year decrease of 1426.68%. This contributed to the annual value of $25.8 million for FY2024, which is 649.48% down from last year.
  • Per Cytosorbents' latest filing, its Non-Current Assets stood at $24.4 million for Q3 2025, which was down 2169.3% from $25.0 million recorded in Q2 2025.
  • Cytosorbents' Non-Current Assets' 5-year high stood at $31.5 million during Q2 2024, with a 5-year trough of $7.8 million in Q1 2021.
  • Over the past 5 years, Cytosorbents' median Non-Current Assets value was $27.4 million (recorded in 2022), while the average stood at $26.2 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 24952.52% in 2022, then crashed by 2169.3% in 2025.
  • Quarter analysis of 5 years shows Cytosorbents' Non-Current Assets stood at $25.2 million in 2021, then rose by 16.86% to $29.5 million in 2022, then fell by 6.49% to $27.6 million in 2023, then dropped by 6.49% to $25.8 million in 2024, then fell by 5.17% to $24.4 million in 2025.
  • Its Non-Current Assets stands at $24.4 million for Q3 2025, versus $25.0 million for Q2 2025 and $25.4 million for Q1 2025.